Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic s Q1 Loss Narrows 89 Percent Despite 6-Percent Revenue Decline ...

NEW YORK, May 3 (GenomeWeb News) - Transgenomic today reported a steep cut in net losses despite posting a minor decline in revenues during the first quarter. 


Transgenomic's reported revenues of $6.5 million for the quarter ended March 31, down 6 percent from the $6.9 million year over year. Interim CEO Mike Summers in a statement attributed the decrease in revenues to foreign currency fluctuations.


Transgenomic said that it spent $604,000 on R&D expenses for the first quarter, roughly even with the $606,000 it spent for the same period last year.


Net loss for the period narrowed 89 percent to $318,000 from $2.9 million in the year-ago period.


As of March 31, Transgenomic had $6.6 million in cash and cash equivalents.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.